Oncotelic Therapeutics, Inc. (OTLC) Research

Oncotelic Therapeutics, Inc., an Agoura Hills, California-based clinical-stage biopharmaceutical company, specializes in developing therapeutics for rare oncological conditions. Its flagship therapeutic candidate, OT-101 – an antisense compound designed to inhibit TGF-ß2 – is currently undergoing Phase 3 clinical trials for both pancreatic cancer and glioblastoma. Beyond oncology, OT-101 is also being explored for its potential in treating various viral diseases, including severe acute respiratory syndrome (SARS) and coronaviruses. The company's pipeline further includes OXi4503, which is being advanced for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), and CA4P, intended for the treatment of advanced metastatic melanoma.

Market snapshot

Symbol
OTLC
Price
$0.05
Day change
+11.11%
Market cap
$22.2M
P/E ratio
0.09x
52-week range
0.02-0.11
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months

Peer companies

  • Arch Biopartners Inc. (ACHFF)
  • Cannabix Technologies Inc. (BLOZF)
  • Covalon Technologies Ltd. (CVALF)
  • C21 Investments Inc. (CXXIF)
  • Helix BioPharma Corp. (HBPCF)
  • Amplia Therapeutics Limited (INNMF)
  • PsyBio Therapeutics Corp. (PSYBF)
  • MindMaze Therapeutics Holding S.A. (RLFTF)

Recent insider activity

  • Trieu Vuong — P-Purchase (239759 shares) on 2026-06-17
  • Trieu Vuong — P-Purchase (96000 shares) on 2026-06-15
  • Trieu Vuong — A-Award (4426 shares) on 2026-01-22
  • Trieu Vuong — A-Award (4065 shares) on 2025-11-17
  • Trieu Vuong — P-Purchase (94736 shares) on 2025-07-08

Open Oncotelic Therapeutics, Inc. (OTLC) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.